Latest Xyrem Stories
DUBLIN, Jan. 5, 2015 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the 33(rd) Annual J.P.
Expects to complete submission in the first half of 2015 DUBLIN, Dec.
Trial Initiated in Response to a FDA Pediatric Written Request to Study Xyrem in Children and Adolescents DUBLIN, Dec.
Posters Include an Epidemiological Measure of the Effectiveness Analysis of Defibrotide from a Phase 3 Trial in Severe Hepatic VOD, as well as Updates from an International Compassionate Use Program
Company Reports Second Quarter 2014 Total Revenues of $291 Million, Driven by Strong Sales of Xyrem, Erwinaze and Defitelio DUBLIN, Aug.
Jazz Pharmaceuticals owns worldwide rights to defibrotide DUBLIN, Aug.
DUBLIN, July 22, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2014 second quarter financial results on Tuesday, August 5, 2014,
Jazz Pharmaceuticals to own worldwide rights to defibrotide at closing DUBLIN, July 2, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company
- The word or words serving to define another word or expression, as in a dictionary entry.